Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort |
| |
| Authors: | Tanya Simuni MD Andrew Siderowf MD MSCE Shirley Lasch BS MBA Chris S. Coffey PhD Chelsea Caspell‐Garcia MS Danna Jennings MD Caroline M. Tanner MD PhD John Q. Trojanowski MD PhD Leslie M. Shaw PhD John Seibyl MD Norbert Schuff PhD Andrew Singleton PhD Karl Kieburtz MD MPH Arthur W. Toga PhD Brit Mollenhauer MD Doug Galasko MD Lana M. Chahine MD Daniel Weintraub MD Tatiana Foroud PhD Duygu Tosun PhD Kathleen Poston MD MS Vanessa Arnedo Mark Frasier PhD Todd Sherer PhD Sohini Chowdhury Kenneth Marek MD the Parkinson's Progression Marker Initiative |
| |
| Affiliation: | 1. Northwestern University, Chicago, Illinois, USA;2. University of Pennsylvania, Philadelphia, Pennsylvania, USA;3. Institute for Neurodegenerative Disorders, New Haven, Connecticut, USA;4. University of Iowa, Iowa City, Iowa, USA;5. Eli Lilly, Indianapolis, Indiana, USA;6. University of California, San Francisco, California, USA;7. National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA;8. Clinical Trials Coordination Center, University of Rochester, Rochester, New York, USA;9. University of Southern California, Los Angeles, California, USA;10. Paracelsus‐Elena Klinik, Kassel, Germany;11. University of California, San Diego, California, USA;12. Indiana University, Indianapolis, Indiana, USA;13. Stanford University Medical Center, Stanford, California, USA;14. Michael J Fox Foundation, New York, NY, USA |
| |
| Abstract: | Objective: The objective of this study was to assess longitudinal change in clinical and dopamine transporter imaging outcomes in early, untreated PD. Methods: We describe 5‐year longitudinal change of the MDS‐UPDRS and other clinical measures using results from the Parkinson's Progression Markers Initiative, a longitudinal cohort study of early Parkinson's disease (PD) participants untreated at baseline. We also provide data on the longitudinal change in dopamine transporter 123‐I Ioflupane striatal binding and correlation between the 2 measures. Results: A total of 423 PD participants were recruited, and 358 remain in the study at year 5. Baseline MDS‐UPDRS total score was 32.4 (standard deviation 13.1), and the average annual change (assessed medications OFF for the treated participants) was 7.45 (11.6), 3.11 (11.7), 4(11.9), 4.7 (11.1), and 1.74(11.9) for years 1, 2, 3, 4, and 5, respectively (P < .0001 for the change over time), with a steeper change in year 1. Dopaminergic therapy had a significant effect on the change of MDS‐UPDRS. There was a significant longitudinal change in dopamine transporter binding in all striatal regions (P < .001). There was a significant but weak correlation between MDS‐UPDRS and dopamine transporter binding at baseline and years 1, 2, and 4, but no correlation between the rate of change of the 2 variables. Conclusions: We present 5‐year longitudinal data on the change of the MDS‐UPDRS and other clinical and dopamine transporter imaging outcome measures in early PD. These data can be used for sample size estimates for interventional studies in the de novo PD population. © 2018 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society. |
| |
| Keywords: | Parkinson's disease disease subtypes tremor dominant postural instability gait disorder predominant |
|
|
